


## CRA-2059

<b>Cat. No.:</b>	HY-19303
<b>CAS No.:</b>	256649-36-2
<b>Molecular Formula:</b>	C <sub>34</sub> H <sub>46</sub> N <sub>12</sub> O <sub>8</sub>
<b>Molecular Weight:</b>	750.8
<b>Target:</b>	Ser/Thr Protease
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

<b>Description</b>	CRA-2059 is a highly specific and selective tryptase inhibitor, with a K <sub>i</sub> of 620 pM for recombinant human tryptase-β (rHTβ) <sup>[1]</sup> [2].
<b>In Vitro</b>	Tryptase is a trypsin-like serine protease found as a major protein component in human mast cell secretory granules. CRA-2059 has the potential for inflammatory bowel disease research <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

- [1]. Tremaine WJ, et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. *Aliment Pharmacol Ther.* 2002;16(3):407-413.
- [2]. Selwood T, et al. Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor. *Biol Chem.* 2003;384(12):1605-1611.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA